Back to top
more

Aduro Biotech, Inc. (ADRO)

(Delayed Data from NSDQ)

$4.26 USD

4.26
328,546

+0.11 (2.65%)

Updated May 3, 2019 04:00 PM ET

After-Market: $4.27 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Amicus' (FOLD) Q4 Earnings Miss Estimates, Sales Surpass

Amicus (FOLD) posts a wider-than-expected loss, while sales beat estimates in the fourth quarter of 2019.

Is Aduro Biotech (ADRO) Stock Outpacing Its Medical Peers This Year?

Is (ADRO) Outperforming Other Medical Stocks This Year?

Oncolytics (ONCY) to Report Q4 Earnings: What's in Store?

During Q4 investors' call, Oncolytics (ONCY) is likely to provide an update on the studies of pelareorep, which is being developed for treating solid tumors and hematological malignancies.

ACADIA (ACAD) Q4 Earnings Surpass, Nuplazid Drives Sales

ACADIA (ACAD) beats on earnings and revenues in the fourth quarter.

Global Blood (GBT) Q4 Earnings Miss, Voxelotor Gets FDA Nod

Global Blood (GBT) reports wider-than-expected loss in the fourth quarter of 2019. The FDA approves voxelotor (Oxbryta) for the treatment of SCD in adults, and children 12 years of age and older.

Horizon Therapeutics' (HZNP) Q4 Earnings Beat Estimates

Horizon Therapeutics (HZNP) beat earnings and sales estimates in the fourth quarter of 2019.

Intercept (ICPT) Q4 Earnings Miss, Revenues Beat Estimates

Intercept (ICPT) incurs wider loss in the fourth quarter while sales top mark. Shares fall probably as the action date for OCA's NDA to treat fibrosis due to NASH gets extended by the FDA.

Proteostasis (PTI) to Report Q4 Earnings: What's in Store?

We expect Proteostasis Therapeutics (PTI) to provide updates on its pipeline when its releases fourth-quarter 2019 results.

What in Store for Universal Health's (UHS) Q4 Earnings?

Universal Health's (UHS) Q4 results are likely to reflect gains from both its Acute Care and Behavioral Health segments.

NuCana (NCNA) to Report Q4 Earnings: What's in the Cards?

We expect NuCana (NCNA) to provide updates on its pipeline when it releases fourth-quarter results.

Epizyme (EPZM) Q4 Earnings Miss Estimates, Revenues Beat

Epizyme (EPZM) reports wider-than-expected loss in the fourth quarter of 2019. Nonetheless, its sales beat estimates.

Actinium (ATNM) to Report Q4 Earnings: What's in the Cards?

Investors will focus on revenue growth and other pipeline updates, when Actinium (ATNM) reports fourth-quarter 2019 results.

Tilray (TLRY) to Report Q4 Earnings: What's in the Cards?

Investors will focus on revenue growth and other pipeline updates, when Tilray (TLRY) reports fourth-quarter 2019 results.

Is a Beat in Store for Perrigo (PRGO) This Earnings Season?

Perrigo's (PRGO) Consumer Self Care Americas segment is expected to have aided the company's top line in the soon-to-be-reported quarter.

Cronos (CRON) to Report Q4 Earnings: What's in the Cards?

Investors will focus on Cronos' (CRON) regular top- and bottom-line numbers, along with its pipeline progress, when it reports Q4 results.

What's in Store for Tenet Healthcare's (THC) Q4 Earnings?

Tenet Healthcare's (THC) Q4 results are likely to reflect higher revenues, aided by its Hospital and Other Operations as well as Ambulatory segments, partly offset by lower admissions.

Repligen (RGEN) Stock Down Despite Q4 Earnings & Sales Beat

Repligen's (RGEN) beats on both earnings and revenues in Q4. However, stock declines.

MEDNAX (MD) Q4 Earnings and Revenues Surpass Estimates

Mednax's (MD) Q4 results reflect growth in same unit revenues and lower general and administrative expenses.

bluebird (BLUE) Q4 Earnings Miss Estimates, Revenues In Line

bluebird (BLUE) reports a wider-than-expected loss and in-line revenues for the fourth quarter of 2019.

What's in Store for Select Medical's (SEM) Q4 Earnings?

Select Medical's (SEM) Q4 results are likely to reflect revenue growth across all its segments, increase in expenses and share buyback.

Deere (DE) to Report Q1 Earnings: What's in the Offing?

Deere's (DE) Q1 results likely to reflect benefits from advanced technologies, precision agriculture and cost management despite a choppy agricultural sector.

Aduro Biotech (ADRO) Up 7.5% Since Last Earnings Report: Can It Continue?

Aduro Biotech (ADRO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Aduro (ADRO) Q3 Loss Wider Than Expected, Revenues Rise Y/Y

Aduro's (ADRO) loss misses estimates in Q3 while revenues almost match the mark.

Aduro Biotech (ADRO) Reports Q3 Loss, Tops Revenue Estimates

Aduro Biotech (ADRO) delivered earnings and revenue surprises of -13.04% and 5.47%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Why Is Aduro Biotech (ADRO) Down 12.1% Since Last Earnings Report?

Aduro Biotech (ADRO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.